Abediterol	salbutamol	peak FEV1	2293	2537	Abediterol 0.625–2.5 μg provided dose-dependent, clinically and statistically significant bronchodilation versus placebo in patients with asthma, with a peak effect similar to salbutamol and duration of action compatible with once-daily dosing.
Abediterol	placebo	peak FEV1	1360	1591	Abediterol produced dose-dependent improvements in peak FEV1 from baseline compared with placebo, from 0.274 (95% CI 0.221, 0.327) to 0.405 L (95% CI 0.353, 0.458) for abediterol 0.313 to 2.5 μg, respectively (p < 0.0001 all doses)
Abediterol	salbutamol	peak FEV1	1593	1684	Abediterol 0.625, 1.25, and 2.5 μg had similar magnitude of peak FEV1 effect to salbutamol.
Abediterol	placebo	peak FEV1	-1	-1	All abediterol doses achieved significant improvements versus placebo in FEV1 AUC 0�??6, 0�??12, and 0�??24 h, and peak and trough FVC (p�??<�??0.05).
Abediterol	placebo	Change from baseline in normalized FEV1 AUC0–6, FEV1 AUC0–12, and FEV1 AUC0–2	20989	21202	Change from baseline in normalized FEV1 AUC0–6, FEV1 AUC0–12, and FEV1 AUC0–24 was significantly higher for all doses of abediterol versus placebo (p < 0.0001 for all, Table 2), with dose-related effects observed.
Abediterol	placebo	Dose-dependent changes from baseline in trough FEV1	-1	-1	Dose-dependent changes from baseline in trough FEV1 versus placebo were 0.219 (95% CI 0.136, 0.302) to 0.400 L (95% CI 0.317, 0.483) for abediterol 0.313 to 2.5 ?g, respectively (p?<?0.0001).
